In a mouse model, with TC-1 tumor cells (expressing E6 and E7), the number of E7-specific CD8+ T-cells was found to be increased when α-GalCer was administered as an adjuvant in addition to DNA vaccine encoding the HPV16 E7 oncoprotein; in addition, this treatment generated potent anti TC-1 tumor effects [60] (Table 1). The gene discussed is CD8A; the disease is neoplasm.